Model Medicines partners with Sandford Prebys Medical

By The Science Advisory Board staff writers

Artificial intelligence (AI) drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.

The collaboration leverages Model Medicines' ActivPred AI drug discovery platform with Sanford Burnham Prebys' identification of novel antiviral targets and scientific expertise to discover and develop new treatments for SARS-CoV-2 and other infectious diseases. The digital chemistry drug development platform identifies novel biological targets that cannot be resolved with traditional high-throughput screening approaches.

Financial details of the collaboration were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?